Aptevo Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Dec 2025
Net Income -$26MTTM through 31 Dec 2025
Free Cash Flow -$25.6MTTM through 31 Dec 2025
Margins
| Current |
|---|
Returns
-149.4%ROE
-95.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.81x
Net Debt-$21.6Mnet cash position
Cash & Equivalents$21.6M
Quality Metrics
Earnings-Beat Rate33.3%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.